Top in endocrinology: Fenofibrate and heart failure outcomes; the ‘obesity paradox’
Click Here to Manage Email Alerts
Fenofibrate was associated with a reduction in heart failure hospitalizations and cardiovascular-related mortality compared with placebo in patients with type 2 diabetes who received simvastatin, according to recent data.
Researchers said the effect of fenofibrate was primarily observed in patients with standard background glucose-lowering therapy. It was the top story in endocrinology last week.
Another top story was about a clinical trial that tested the so-called “obesity paradox” — the beneficial outcome observed in acute medical conditions for patients with obesity — among patients who were hospitalized with community-acquired pneumonia. According to researchers, patients with obesity did not have a reduced time to clinical stability vs. those with normal weight.
Read these and more top stories in endocrinology below:
Fenofibrate may lower heart failure hospitalization, CV mortality in type 2 diabetes
In a cohort of patients with type 2 diabetes treated with simvastatin, fenofibrate decreased the composite of heart failure hospitalizations or cardiovascular mortality, according to an analysis of the ACCORD Lipid trial. Read more.
Obesity does not confer benefit in community-acquired pneumonia
Among patients hospitalized with community-acquired pneumonia, those with obesity did not experience an improved time to clinical stability compared with their normal-weight counterparts, according to study data. Read more.
Combination SGLT2, GLP-1 therapy lowers risk for adverse CV outcomes in type 2 diabetes
Combined use of an SGLT2 inhibitor and GLP-1 receptor agonist is associated with reduced odds for major adverse cardiac and cerebrovascular events and heart failure in adults with type 2 diabetes, according to study findings. Read more.
Immunohistochemistry-guided sequencing finds mutations in most cortisol-producing adenomas
The use of an immunohistochemistryguided targeted amplicon sequencing approach using formalin-fixed, paraffin-embedded tissue detected somatic mutations in more than 70% of cortisol-producing adenomas, according to study data. Read more.
Lowering HbA1c during pregnancy may reduce risks for adverse neonatal outcomes
By reducing HbA1c during pregnancy, women with pregestational diabetes may reduce their risks for having an infant born large for gestational age or with neonatal hypoglycemia, according to study results published in Diabetic Medicine. Read more.